
MDAI Stock Forecast & Price Target
MDAI Analyst Ratings
Bulls say
Spectral AI is viewed positively because FDA clearance for the DeepView System materially de-risks a platform that has been in development and clinical investigation for numerous years, while also setting up a commercial launch in 2H26. The investment case is strengthened by BARDA support, including ~$31.7M of funding in March 2026, planned distribution of ~30 systems, and potential subsidy for an additional ~140 systems, which should aid early adoption and reduce execution risk. With a targeted U.S. addressable market of ~125 Burn Centers and ~5,000 Trauma and ED units, plus FY26 revenue guidance of $18.5M and a modeled 110% CAGR in FY26 through FY30, the company offers a high-upside growth profile in a large, under-penetrated medtech niche.
Bears say
Spectral AI is viewed negatively because its revenue outlook is highly exposed to clinical and regulatory delays, which could reduce BARDA-related revenue and push out commercialization. The company also faces meaningful execution risk from setbacks in approvals that could require additional analysis, filings, or more clinical data, while adoption of the DeepView system in a commercial setting may remain limited. More broadly, limited technology awareness, a short operating history, competition, limited reimbursement, cybersecurity risk, and the potential need for additional capital all weaken the fundamental risk-reward profile.
This aggregate rating is based on analysts' research of Spectral AI Inc and is not a guaranteed prediction by Public.com or investment advice.
MDAI Analyst Forecast & Price Prediction
Start investing in MDAI
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Spectral AI Inc (MDAI) Forecast
MDAI Analyst Forecast & Price Prediction
Start investing in MDAI
Order type
Buy in
Order amount
Est. shares
0 shares